BRAF and chronic myelogenous leukemia, BCR-ABL1 positive: Besides ABL in CML, Ponatinib strongly inhibits other kinases such as FGFR, FLT3, KIT, and PDFGRα (Supplementary Fig. 3)34–36 and it was previously reported in kinome screens to inhibit BRAF activity, however, it is not validated or recognized as BRAF inhibitor13,37.